HS-X01

HS-X01 is an early-stage therapeutic candidate being developed by HaplnScience, a South Korean biotechnology company specializing in tissue regeneration. The candidate is part of the company's pipeline focused on the HAPLN1 (Hyaluronan and Proteoglycan Link Protein 1) platform. HAPLN1 is a key component of the extracellular matrix (ECM) that stabilizes the interaction between hyaluronan and proteoglycans, maintaining tissue structural integrity. As HAPLN1 levels decline with aging, HaplnScience's therapeutic approach involves using recombinant HAPLN1 to restore ECM integrity and promote tissue repair. HS-X01 is specifically identified in the context of collaborative research and development, though its specific primary indication and detailed pharmacological profile have not been publicly disclosed as of the current pipeline updates.